OrthoPediatrics (NASDAQ:KIDS) Given New $32.00 Price Target at Stifel Nicolaus

OrthoPediatrics (NASDAQ:KIDS) had its price objective reduced by stock analysts at Stifel Nicolaus from $40.00 to $32.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target indicates a potential upside of 33.39% from the company’s previous close.

Several other research analysts also recently commented on KIDS. Needham & Company LLC restated a “buy” rating and set a $42.00 price objective on shares of OrthoPediatrics in a report on Wednesday. Truist Financial cut their price target on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th.

OrthoPediatrics Trading Up 4.8 %

KIDS stock traded up $1.10 during midday trading on Wednesday, reaching $23.99. The company’s stock had a trading volume of 30,199 shares, compared to its average volume of 315,243. The firm has a market capitalization of $580.94 million, a price-to-earnings ratio of -19.50 and a beta of 1.14. OrthoPediatrics has a 1 year low of $21.02 and a 1 year high of $35.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The stock has a fifty day simple moving average of $24.39 and a two-hundred day simple moving average of $25.94.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. The company had revenue of $52.67 million for the quarter, compared to the consensus estimate of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same quarter last year, the firm posted ($0.23) EPS. On average, equities research analysts predict that OrthoPediatrics will post -0.93 EPS for the current year.

Institutional Trading of OrthoPediatrics

Several large investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in shares of OrthoPediatrics during the third quarter worth about $25,000. International Assets Investment Management LLC boosted its holdings in shares of OrthoPediatrics by 2,610.8% in the 3rd quarter. International Assets Investment Management LLC now owns 1,003 shares of the company’s stock valued at $27,000 after acquiring an additional 966 shares during the last quarter. R Squared Ltd acquired a new stake in OrthoPediatrics during the 4th quarter worth about $48,000. KLP Kapitalforvaltning AS purchased a new position in OrthoPediatrics during the fourth quarter valued at approximately $79,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of OrthoPediatrics by 125.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock valued at $94,000 after purchasing an additional 1,929 shares during the period. Hedge funds and other institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.